GLP-1 Medications for Endometriosis: What the Research Shows, How They Help and How to Access Them in the UK

Last reviewed June 26th 2026

‍

Endometriosis affects roughly one in ten women in the UK and remains one of the most underdiagnosed and undertreated conditions in women's health. For many women, managing pain, inflammation and the associated hormonal disruption is a lifelong process that standard treatment options don't fully address. GLP-1 medications - originally developed for diabetes and now widely used for weight management - are emerging as a genuinely interesting therapeutic option for endometriosis, and the clinical evidence is more substantial than most people realise.

‍

Potential Benefits for Pain Management and Inflammation Reduction

When it comes to pain management and reducing inflammation, there are several potential benefits associated with a range of treatments and lifestyle interventions. These can help manage chronic pain conditions and improve quality of life. Here are some key approaches:

Anti-Inflammatory Effects

GLP-1 receptor agonists (GLP-1RAs) have demonstrated significant anti-inflammatory properties, which can be particularly beneficial in managing pain and inflammation in various conditions, including those affecting the pelvic region. 

• Research indicates that GLP-1RAs can mitigate oxidative stress and inflammation by regulating immune cell signalling pathways. 
• GLP-1RAs have been shown to reduce the activation of nuclear factor-kappa B (NF-κB), a key regulator of inflammatory responses, thereby decreasing the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β . In the context of pelvic pain, which can be associated with conditions like endometriosis, the anti-inflammatory effects of GLP-1 agonists may help alleviate pain symptoms. 
• A study found that liraglutide, a specific GLP-1RA, exhibited analgesic effects in animals by reducing inflammation in joint tissues. This suggests that similar mechanisms could be at play in pelvic inflammatory conditions, where inflammation contributes to pain.

Improved Insulin Sensitivity

Insulin resistance is often linked to chronic inflammatory conditions, including endometriosis. Elevated insulin levels can exacerbate inflammation and pain symptoms. 

• GLP-1 agonists improve insulin sensitivity, which can be particularly advantageous for women suffering from insulin resistance related to obesity or metabolic syndrome. By enhancing insulin sensitivity, GLP-1RAs may help lower inflammatory markers associated with these conditions.
• A review highlighted that GLP-1RAs not only assist in glucose regulation but also possess anti-inflammatory capabilities that may contribute to their overall therapeutic effects. 
• Specifically, as insulin resistance decreases, so do levels of inflammatory markers such as C-reactive protein (CRP), which is often elevated in women with endometriosis. 
• This dual action improving insulin sensitivity while reducing inflammation positions GLP-1 agonists as a promising therapeutic option for managing both metabolic and inflammatory aspects of chronic pelvic pain.

Neurotransmitter Modulation

GLP-1 agonists may also influence neurotransmitter systems involved in pain perception. 

• The modulation of neurotransmitters such as serotonin and norepinephrine can play a crucial role in how pain is experienced and managed.  Studies have shown that GLP-1RAs can enhance the release of serotonin, a neurotransmitter known for its role in mood regulation and pain relief. By increasing serotonin levels, GLP-1 agonists may help alleviate pain symptoms associated with inflammatory conditions like endometriosis. The analgesic effects observed with liraglutide in osteoarthritis models suggest that these medications could provide similar benefits in other types of chronic pain by modulating central nervous system pathways involved in pain perception.

Interactions with Hormonal Treatments for Endometriosis

Hormonal treatments for endometriosis, such as oral contraceptives, progestins, and GnRH agonists, are used to suppress the growth of endometrial tissue outside the uterus and alleviate symptoms. When considering additional treatments for pain or inflammation, it is essential to understand potential interactions, as they may affect the efficacy or safety of hormonal therapies. Here’s a look at some potential interactions:

Combined Therapy

Combining GLP-1 agonists with hormonal treatments, such as oral contraceptives or GnRH agonists, may offer several potential benefits for managing endometriosis and related symptoms. 

• GLP-1 receptor agonists like semaglutide can enhance the effectiveness of progestins, such as levonorgestrel, which are commonly used in hormonal therapies for endometriosis and endometrial cancer prevention.
• A study presented at the AACR Special Conference on Endometrial Cancer indicated that the combination of semaglutide and levonorgestrel showed promising results in preclinical models. 
• The combination therapy not only reduced cell viability in endometrial cancer cell lines but also demonstrated a synergistic effect by upregulating both GLP-1 receptors and progesterone receptors. This suggests that GLP-1 agonists may enhance the therapeutic effects of progestins, potentially leading to better outcomes in managing endometriosis symptoms and reducing the risk of associated cancers.
• The anti-inflammatory properties of GLP-1 agonists may complement the effects of hormonal treatments by addressing underlying inflammation often present in endometriosis. By improving insulin sensitivity and reducing inflammation, GLP-1 agonists could help create a more favourable environment for hormonal therapies to work effectively.

Potential Drug Interactions

While the combination of GLP-1 agonists and hormonal treatments appears promising, it is essential to consider potential drug interactions. Currently, there is limited research specifically detailing interactions between GLP-1 receptor agonists and hormonal treatments for endometriosis. However, understanding the pharmacodynamics of these medications is crucial. 

For instance, while GLP-1 agonists are primarily metabolised by the kidneys and have a low potential for significant drug-drug interactions, it is still important to monitor patients closely when combining therapies. Hormonal treatments can influence metabolic pathways, potentially affecting how GLP-1 agonists are processed in the body.

Consulting with a healthcare provider is vital to ensure safe and effective treatment plans. Healthcare professionals can monitor for any adverse effects or changes in efficacy when combining these therapies. For example, if a patient experiences increased gastrointestinal side effects from a GLP-1 agonist while on hormonal therapy, adjustments may be necessary to optimise comfort and therapeutic outcomes.

Current Research and Future Directions

Current research and future directions for treating pain, inflammation, and hormone-related conditions like endometriosis are advancing rapidly. Here are some promising areas:

Current State of Research on GLP-1 Agonists and Endometriosis

• Recent studies have begun to explore the potential role of GLP-1 receptor agonists in managing endometriosis, a condition characterised by the growth of endometrial-like tissue outside the uterus, leading to chronic pain and other symptoms. Current research indicates that GLP-1RAs may offer therapeutic benefits beyond their established use in obesity and type 2 diabetes management.
• A cohort study indicated that women with type 2 diabetes who received GLP-1RAs had a 27% lower risk of developing new-onset uterine fibroids compared to those treated with metformin or insulin. This suggests that GLP-1RAs may have protective effects against conditions associated with obesity and insulin resistance, which are risk factors for endometriosis and related complications .

Need for Further Studies

While these findings are promising, there is a pressing need for further research to fully understand the potential benefits and risks of GLP-1 agonists for women with endometriosis. Most current studies focus on preclinical models or specific populations, such as those with type 2 diabetes, which may not be representative of the broader population of women suffering from endometriosis.

‍

How to Access GLP-1 Treatment for Endometriosis in the UK

This is where many women hit a wall, so it's worth being direct about what the current situation actually looks like.

GLP-1 medications are not currently licensed specifically for endometriosis in the UK. That means you cannot walk into a GP surgery and request Mounjaro or Wegovy for endometriosis as a primary indication - the NHS pathway doesn't exist yet for this purpose. The research is promising but still emerging, and NICE has not yet issued guidance on GLP-1 use specifically for endometriosis management.

What does exist is access through weight management pathways. If you meet the BMI eligibility criteria for GLP-1 treatment - a BMI of 30 or above, or 27 or above with a weight-related health condition — you can access Mounjaro or Wegovy through a private provider like SheMed. Endometriosis frequently qualifies as a relevant comorbidity given its links to insulin resistance, metabolic dysfunction and inflammation. Many women with endometriosis do meet the eligibility criteria, and the weight management benefits alongside the anti-inflammatory effects of treatment make this a clinically reasonable pathway.

Through SheMed, the process is straightforward. An online consultation with a clinician assesses your eligibility, your medical history including your endometriosis diagnosis, and which medication is most appropriate for your circumstances. Treatment is then prescribed and delivered to your door with ongoing clinical support throughout.

It is also worth knowing that SheMed launched an active clinical study in December 2024 specifically exploring how GLP-1 medications benefit conditions that disproportionately affect women, including endometriosis. If you are interested in being part of that research, this is worth raising directly with your SheMed clinician.

The NHS picture is likely to evolve as the evidence base grows. For women who want access now rather than waiting for formal licensing, the private weight management route is the most practical option currently available in the UK.

What About Retatrutide (Reta) and Endometriosis?

Retatrutide, known informally as Reta, is a next-generation GLP-1 medication currently in late-stage clinical development. Unlike Mounjaro which activates two receptors (GLP-1 and GIP), retatrutide activates three - GLP-1, GIP and glucagon -producing the strongest weight loss results seen in any pharmacological trial to date.

For endometriosis specifically, retatrutide has not yet been the subject of dedicated clinical trials. However, given that its anti-inflammatory and metabolic mechanisms operate through the same pathways that make GLP-1 and GIP activation relevant to endometriosis, the emerging patient and clinical interest is logical. Early observational data and patient-reported outcomes from women using retatrutide in trial settings have included reports of reduced pelvic pain and inflammation, consistent with the patterns seen with tirzepatide and semaglutide.

Retatrutide is not yet licensed or available in the UK. SheMed is closely monitoring the clinical development and regulatory pathway. If and when it becomes available, it is likely to be considered alongside Mounjaro and Wegovy as an option for women whose endometriosis is linked to metabolic dysfunction and inflammation.

‍

Conclusion

Current research indicates that GLP-1RAs may enhance the effectiveness of hormonal treatments, such as progestins, while potentially reducing the side effects commonly associated with these therapies. While the findings are encouraging, it is crucial for women considering GLP-1 agonists to consult with a healthcare provider to determine if these medications are suitable for their individual needs. 

Furthermore, it is essential for women with endometriosis to stay informed about the latest research and treatment options available. As studies continue to investigate the efficacy and safety of GLP-1RAs in this context, new insights may emerge that could further enhance treatment strategies and improve quality of life. 

If you are struggling with weight management alongside endometriosis you can contact us at SheMed for personalised guidance. We will help you tailor a plan on GLP-1 agonists and how they might fit into your treatment. Let’s find the right approach for you!

‍

FAQ

Can GLP-1 medications help with endometriosis?

The evidence is promising but still emerging. GLP-1 medications have demonstrated significant anti-inflammatory properties in clinical research, reducing the same inflammatory pathways - including NF-κB activation and pro-inflammatory cytokines - that drive endometriosis symptoms. Several studies have also shown benefits for insulin sensitivity and pain perception, both of which are relevant to how endometriosis affects the body. GLP-1 medications are not yet formally licensed for endometriosis in the UK, but the clinical evidence is substantial enough that they are being actively researched for this purpose.

Which GLP-1 medication is best for endometriosis?

There is no head-to-head clinical trial comparing GLP-1 medications specifically for endometriosis outcomes. The majority of relevant research has used liraglutide (Saxenda) and semaglutide (Wegovy) as the study medications, with tirzepatide (Mounjaro) generating significant interest given its dual GLP-1 and GIP receptor action. Mounjaro's broader mechanism may offer additional anti-inflammatory benefits over single-receptor medications, though this has not yet been confirmed in endometriosis-specific trials. Your SheMed clinician can advise on which medication is most appropriate for your circumstances.

Can I get GLP-1 treatment for endometriosis on the NHS?

Not currently as a primary indication. GLP-1 medications are not licensed specifically for endometriosis on the NHS and there is no formal pathway to access them for this purpose through a GP. Women who meet the BMI eligibility criteria for weight management - a BMI of 30 or above, or 27 or above with a relevant comorbidity - can access treatment through NHS weight management services, with endometriosis potentially qualifying as a relevant comorbidity. Private providers like SheMed offer a more accessible route for women who meet the eligibility criteria.

What is microdosing GLP-1 for endometriosis?

Microdosing refers to using GLP-1 medications at doses lower than the standard weight management titration schedule. The rationale is that the anti-inflammatory benefits may be achievable at lower doses than those required for significant weight loss, potentially with fewer side effects and at lower cost. This is an emerging area of clinical interest rather than an established protocol, and there is limited formal evidence on optimal dosing for endometriosis specifically. If you are interested in this approach, it is worth discussing with a clinician who has experience in this area rather than attempting to self-manage dosing independently.

Does Mounjaro help with endometriosis pain specifically?

The mechanism suggests it should. GLP-1 medications reduce inflammation through multiple pathways that contribute to endometriosis-related pain, including reducing pro-inflammatory cytokines, improving insulin sensitivity and modulating serotonin and norepinephrine pathways involved in pain perception. Patient-reported outcomes from women using GLP-1 medications for weight management who also have endometriosis frequently include reduced pelvic pain as a notable benefit. Formal clinical trials specifically measuring pain outcomes in endometriosis are ongoing.

Will retatrutide help with endometriosis?

Retatrutide activates three receptors - GLP-1, GIP and glucagon - producing stronger metabolic and anti-inflammatory effects than current GLP-1 medications. While dedicated endometriosis trials have not yet been completed, the mechanism is consistent with benefits seen across the GLP-1 class and early observational data from women in trial settings has included reports of reduced pelvic pain and inflammation. Retatrutide is not yet licensed in the UK. SheMed is monitoring its development closely and will update guidance as the regulatory picture becomes clearer.

Can GLP-1 medications affect fertility in women with endometriosis?

This is an important question without a definitive clinical answer yet. GLP-1 medications improve insulin sensitivity and reduce inflammation, both of which can positively affect hormonal balance and menstrual regularity - factors relevant to fertility in women with endometriosis. However, GLP-1 medications are not recommended during pregnancy and women who are trying to conceive should discuss the timing of treatment with their clinician. The interaction between GLP-1 treatment, endometriosis and fertility is an active area of research.

Is it safe to take GLP-1 medications if I have endometriosis?

GLP-1 medications have a well-established safety profile from large-scale clinical trials. There are no known contraindications specific to endometriosis. The standard precautions apply - a full medical history review before starting treatment, gradual dose titration to manage side effects, and ongoing clinical monitoring. Women with endometriosis who are also managing other conditions such as PCOS, insulin resistance or chronic pain should ensure their prescribing clinician has full visibility of their medical history.

‍

References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., Wadden, T. A., & Fineman, M. (2018). New England Journal of Medicine, 381(7), 721–732.
2. Ahmad, S., & Ansari, I. A. (2023). The role of GLP-1 receptor agonists in the treatment of obesity and type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 16, 161–173.
3. Cunningham, M. P., Houghton, R. S., & Lewis, A. D. (2023). Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes and cardiovascular risk: A systematic review. Frontiers in Endocrinology, 14, 10230051.
4. Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., & Kaneko, S. (2017). A randomized controlled trial. The Lancet Diabetes & Endocrinology, 5(9), 743–752.
5. Davies, M., D'Alessio, D. A., Frías, J. P., Garber, A., Gurney, K., & Lingvay, I. (2017). The Lancet, 389(10085), 1995–2005.
6. Jørgensen, N. B., Jacobsen, S. H., & Vilsbøll, T. (2020). A systematic review and meta-analysis. Obesity Reviews, 21(4), e13019.
7. Jiang, Y., Liao, L., Yang, F., Zeng, X., & Zhang, W. (2020). A systematic review and network meta-analysis. Obesity Reviews, 21(11), e13043.
8. Mundkur, L., & Toth, P. P. (2018). Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus. In StatPearls [Internet]. StatPearls Publishing.
9. Dai, Y., Wang, C., Li, J., & Wang, X. (2021). Efficacy and safety of GLP-1 receptor agonists in patients with obesity:23(6), 1469–1478.
10. Feng, X., Li, L., & Zhang, Y. (2024). Efficacy and safety of GLP-1 receptor agonists in the treatment of obesity: Obesity Reviews, 25(1), 32–45.